Workshops

Development of bio-therapeutics often rely on small-scale single-use bioreactors made from plastics that include versatile connectors for easy connection and fast turnaround. As bio-therapeutic development continues to grow, industry front runners have defined challenging sustainability environmental targets with regards to emissions and are now looking at circularity targets. One of the common objections to plastic circularity in healthcare is the perceived “downcycling” effect of mechanical recycling, although there are material formulations that employ mechanically recycled materials, such as polycarbonate, where material from consumer articles are recovered, granulated and mixed-in with materials targeting demanding applications such as electronic devices. 

Therefore, the aim of this work was to collaboratively establish the technical feasibility of a closed loop recycling concept in bioprocess applications, using Makrolon® as a material of construction for bioreactor vessels.

In this workshop, we focus on achieving both environmental sustainability and patient well-being through innovative pharmaceutical packaging. Aligned with Berry Global’ s dedication to sustainability and innovation, we will discuss practical strategies for creating sustainable medical and pharmaceutical packaging.

• The session begins with an overview of our Impact 2025 initiative, highlighting our efforts to enhance sustainability in both operations and product design.
• We will then delve into the implications of the latest EU Packaging and Packaging Waste Directive on pharmaceutical and medical packaging, and how Berry is effectively responding to these new standards. 
• A significant part of our discussion will be dedicated to a case study comparing pill jars and blister packs, showcasing the superior environmental benefits of pill jars. 
• The workshop concludes with an exploration of Berry's comprehensive range of sustainable packaging solutions, the Bmore portfolio, underlining our leadership in the field of sustainable packaging innovation. 

If you're seeking a supplier to help you meet and exceed your sustainability goals, please join our workshop

The pharmaceutical industry is in a transformation-phase, trying to move from linear to circular economy models. PharmaGuard is recognized as one of the leading polyolefin blister packaging solution, and recently has been rewarded with the ‘Prestigious German Packaging Award’ (Deutscher Verpackungspreis) in the sustainability category.

After its launch early 2023, PharmaGuard has gained lots of market interest, and is recognized as the leading recycle ready solution for the future. With its excellent transparency, good and stable shrinkage behavior, and a wider thermoforming- and sealing window, together with its controllable push-through lidding, PharmaGuard is setting new industry standards.

You will learn more about 

• PharmaGuards’ different segment specific solutions, e.g. for applications with higher barrier demands.

• The environment footprint of different solutions.

• How the pharma industry can significantly reduce carbon emissions in a safe and efficient way.

Edge Technologies, based on RFID (Radio Frequency Identification) and NFC (Near Field Communication) give medical devices and medicines a unique digital identity, and automatically read, sense, store and process, data locally on products, whilst enabling tracking and complex processing in the cloud or private network. The results are optimized logistics, increased product safety, improved patient outcomes and reliable supply chain protection.

NXP, a market leader in security and connectivity solutions, has a successful track record of providing trusted solutions to the healthcare industry, to help enhance people’s lives. Visit our workshop and find out about latest solutions in connected pharma packaging and drug delivery devices, for use in hospitals, clinical trials and patient self-care.

Digital health solutions create myriad possibilities in terms of enabling “beyond the pill” health outcomes. However, the path to streamlining a strategic approach between pharma and its development partners toward creating smart combination products remains a challenge. With a general consensus that developers must accurately determine in advance what users want, many companies wait upon the success of early players as a determinant to foray into digital health. This philosophy, however, disregards the heterogeneity of combination products in development along with the diversity of clinical or patient-reported outcomes measures. Here, we present a dissection of SHL’s Innovation Partnership program along with our connected device offering – both of which allows us to flexibly collaborate with any pharmaceutical partner in the development of connected therapeutics.

Sterile pharmaceutical production is expected to grow by over 50% in the next seven years, driven by new demand for recombinant antibodies and small molecules. Consequently, the fill/finish stage in pharmaceutical manufacturing is becoming a bottleneck in the pharmaceutical production . Health authorities and regulators are also demanding enhanced traceability during the manufacture of parenteral medicines as the most common processes and technologies in place are reaching their limitations . Addressing this challenge means boosting Overall Equipment Efficiency (OEE) while meeting rising regulatory demands.

This presentation explores an innovative solution to address this dual challenge: Container-level traceability (CUID). This pioneering approach utilizes RFID (Radio Frequency Identification) to ensure accountability for each container in the fill-finish processes, down to the individual unit. 

In the short term, CUID can mitigate exposure to mix-up, improve OEE through automated reconciliation, and cut waste with unit-by-unit segregation. Beyond this, CUID has the potential to eliminate data silos and bridge the gap between each manufacturing process step. Manufacturers can harness advanced data analytics to unveil hidden patterns, identify process inefficiencies, and detect trends and anomalies that were previously unnoticed. 

Becton Dickinson selected RFID technology for pre-fillable syringes based on the relatively low impact on existing manufacturing lines and the high potential for future applications. 

In collaboration with Avery Dennison Smartrac, a leading provider of RFID inlay solutions, BD has conducted a proof of concept and will demonstrate the feasibility of the solution through a video of BD’s RFID Demonstration Lab and a live demo.

Get tools for quantifying user input for drug delivery systems – enabling sound choices in the development process.

Imagine an elderly man, your grandfather, managing diabetes and self-injecting at home. While it's a simple task for the young and healthy, it poses challenges for the elderly. Incomplete doses due to premature lifting can lead to non-compliance, jeopardizing their health. Our presentation at Pharmapack addresses key issues in autoinjector usage, focusing on activation. By leveraging the industrial design, activation forces, sound, and visuals, we can enhance the user interface. Our toolbox allows us to frontload user insights, ensuring precise specifications early on in the development project. Explore how the activation profile toolbox validate and optimize the user experience, providing a solution that empowers individuals like your grandfather to use the device correctly every time.

The rising demand for at-home self-administered therapies has made patient-friendly formats, such as autoinjectors, a necessity for drug manufacturers. However, the intricacies of manufacturing these devices pose significant challenges. This presentation offers valuable insights into planning the device assembly and packaging process, enabling drug owners to navigate this evolving landscape with confidence and efficiency.

Drug development, particularly of biologics can be expensive and run over several years. One of the challenges for formulation and clinical development teams is identifying devices for use in early formulation and clinical studies, where the performance characteristics and clinical safety are being assessed, without the device negatively influencing the results.  Having a device platform that can be introduced into the formulation and clinical development as early as necessary with minimal impact on development timelines could go along way to simplifying the product development cycle.